Ling Ma

机构：Yunnan Normal University, Union Hospital, Lanzhou Institute of Chemical Physics, Integrated Chinese Medicine (China), Dalian Municipal Central Hospital, 82th Hospital of Pla, Jiangsu Cancer Hospital, National Center for Clinical Laboratories, Jiangsu Province Hospital, Shenzhen Pingle Orthopedic Hospital, Huazhong University of Science and Technology, Nanjing Medical University, China Medical University · ORCID：0000-0002-1485-8994

发表论文 80 篇 · 总被引 943 次 · h-index 20

代表论文

• Acute Lung Injury and the NLRP3 Inflammasome (2024 · Journal of Inflammation Research · 被引 50)
• Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies (2024 · Molecular Therapy · 被引 29)
• Influence of chain length on the anticancer activity of the antimicrobial peptide CAMEL with fatty acid modification (2022 · European Journal of Medicinal Chemistry · 被引 25)
• Development of Neuropeptide Hemokinin-1 Analogues with Antimicrobial and Wound-Healing Activity (2023 · Journal of Medicinal Chemistry · 被引 12)
• Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy (2024 · Asian Journal of Pharmaceutical Sciences · 被引 9)
• The metabolic score for insulin resistance as a predictor of clinical outcome in stroke patients treated by intravenous thrombolysis (2023 · Neurological Sciences · 被引 8)